Jazz los­es ap­peal, will have patent delist­ed from the Or­ange Book

The US Court of Ap­peals for the Fed­er­al Cir­cuit is up­hold­ing an in­junc­tion that states that a patent re­lat­ed to Jazz Phar­ma­ceu­ti­cals’ nar­colep­sy drug should be delist­ed from the FDA’s gener­ic drug com­pendi­um known as the Or­ange Book.

The patent in ques­tion, called the ‘963 patent, is re­lat­ed to Jazz’s “sin­gle-phar­ma­cy dis­tri­b­u­tion sys­tem” which is de­signed to con­trol ac­cess to drugs pre­scribed to nar­colep­sy pa­tients, which can be abused. The patents in­clude a cen­tral phar­ma­cy and com­put­er data­base that can track pre­scrip­tions and pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.